Phase 4 N=32 Fibrinolysis Compared to Thoracoscopy for Pleural Infection
Pleural Infection · Empyema · Pleural Diseases
Primary: Duration of Hospital Stay After Intervention — 4; 2 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=5 Fibrinolytic Therapy Versus Medical Thoracoscopy
Pleural Diseases
Primary: Number of Hospital Days for Required to Treat Complicated Parapneumonic Effusions or Pleural Empyema. — 13; 18.5 days
N/A N=10 Treatment of Complicated Parapneumonic Effusion With Fibrinolytic Therapy Versus VATs Decortication
Parapneumonic Effusion · Empyema, Pleural · Coagulopathy
Primary: Hospital Length of Stay — 12.4; 8.4 days
Phase 3 N=97 Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
Pleural Empyema
Primary: Time to Hospital Discharge — 9.0; 9.1 days
Phase 4 N=27 Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis
Pleural Effusion
Primary: Chest X-ray Results on Day 3 After Pleurodesis — 5; 6; 5; 8 Participants — p=0.863
N/A N=37 Pleural Manometry for the Characterization of Spontaneous and Tension Pneumothorax
Pneumothorax · Tension Pneumothorax
Primary: Pleural Pressure (Ppl) Prior to Evacuation of Pleural Air — 7.44; -1.79 cmH2O
N/A N=100 Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas
Pleural Effusion Associated With Pulmonary Infection · Bacterial Pleural Effusion Other Than Tuberculosis
Primary: No Surgical Intervention — 66; 6 participants — p=<0.001
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
Early Phase 1 N=17 Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
N/A N=198 Chest Tube Drainage of Transudative Pleural Effusions Hastens Liberation From Mechanical Ventilation
Liberation From Mechanical Ventilation
Primary: Total Days of Mechanical Ventilatory Support — 6.51; 4.02 days
Phase 4 N=121 PleuraSeal Post Market Study (Europe)
Lung Disease · Pulmonary Lobectomy
Primary: Percentage of Subjects Remaining Air Leak Free From Time of Skin Closure to Hospital Discharge. — 41.9; 30.5 Percentage of participants — p=0.257
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
N/A N=25 Catheter Placement for Hepatic Hydrothorax
Pleural Effusion
Primary: Feasibility of Using Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax — 25 Participants
Phase 2 N=20 Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses
Abdominal Abscess · Pelvic Abscess
Primary: Percentage of Patients Requiring Surgical Debridement for a Persistent Abscess Within 30 Days Following Initial Drainage — 3; 7 participants
N/A N=109 Prospective Evaluation of 14F Thal Tube vs 28 French Chest Tube for Hemothorax and Use of Maximum Barrier Precautions
Hemothorax · Hemopneumothorax; Traumatic · Empyema
Primary: Number of Participants With Retained Hemothorax Following Initial Chest Tube Placement Requiring Intervention — 51; 48 Number of Participants — p=0.036
N/A N=251 Efficacy of Post-operative Antibiotic Prophylaxis for Thoracic Surgery Requiring Tube Thoracostomy
Antibiotic Prophylaxis
Primary: Number of Participants Who Experienced At Least One Postoperative Infectious Complication — 13; 8 Participants — p=.26
Phase 2 N=96 Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
Tuberculosis · AIDS-related Complex
Primary: Sputum Conversion — 36; 60; 36 percentage of participants
N/A N=119 Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter
Malignant Pleural Effusion
Primary: The Proportion of Subjects Achieving Pleurodesis Without Recurrence. — 17; 12 Participants
N/A N=59 Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
N/A N=83 Continuous Subpleural Infusion of Bupivacaine
Postoperative Pain
Primary: Number of Participants With and Without 30-Day Pain Medication Usage — 8; 6; 30; 36 participants
N/A N=56 Macrophage Phagocytosis in COPD
Chronic Obstructive Pulmonary Disease · Emphysema · Chronic Bronchitis
Primary: Phagocytosis of H. Influenzae Concentration — 0.042; 0.042; 0.014; 0.06 relative fluorescence unit — p=0.05
Phase 2 N=31 Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
Non-small Cell Lung Cancer · Mesothelioma · Lung Neoplasms
Primary: Overview of Adverse Events — 28; 23; 12; 1 participants
Phase 2 N=98 Human Lung Responses to Respiratory Pathogens
Respiratory Infection
Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)
Phase 4 N=647 Multicenter Infection Surveillance Study Following Open Heart Surgery
Surgery · Pneumonia · Surgical Site Infection
Primary: Hospital Acquired Pneumonia — 8; 18 participants
Phase 3 N=294 Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
Pseudomonas Aeruginosa Infection
Primary: Pulmonary Function Test: Forced Expiratory Volume in 1 Second (FEV1) — 0.47; 1.67 Percent (%) change
Early Phase 1 N=22 Quantifying Airway Inflammation With Radiologic Tests
Lung Inflammation
Primary: Change in Ki (Measure of [18F]Fluorodeoxyglucose ([18F]FDG) Uptake Determined by Patlak Graphical Analysis) in the Right Lung 24 Hours After LPS Instillation — 18.8…
Phase 2 N=32 Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.
Lung Transplant Infection · Lower Respiratory Tract Infection
Primary: Lung Clearance Index 2% (LCI2%) — 10.68; 11.65; 10.09; 11.19 Index (change)
N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Phase 2 N=217 The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
COVID-19
Primary: Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of…
N/A N=197 Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.
Infections, Streptococcal
Primary: Number of Subjects With Bacterial Aetiology, Assessed by Culture Growth, From Bronchoalveolar Lavage (BAL) Fluid Samples — 141; 49; 1; 58 Participants